ZA201905212B - Rescue treatment of post operative nausea and vomiting - Google Patents

Rescue treatment of post operative nausea and vomiting

Info

Publication number
ZA201905212B
ZA201905212B ZA2019/05212A ZA201905212A ZA201905212B ZA 201905212 B ZA201905212 B ZA 201905212B ZA 2019/05212 A ZA2019/05212 A ZA 2019/05212A ZA 201905212 A ZA201905212 A ZA 201905212A ZA 201905212 B ZA201905212 B ZA 201905212B
Authority
ZA
South Africa
Prior art keywords
vomiting
post operative
rescue treatment
operative nausea
treatment
Prior art date
Application number
ZA2019/05212A
Other languages
English (en)
Inventor
Julian Clive Gilbert
Robert William Gristwood
Gabriel Fox
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of ZA201905212B publication Critical patent/ZA201905212B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2019/05212A 2017-02-10 2019-08-07 Rescue treatment of post operative nausea and vomiting ZA201905212B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1702250.0A GB201702250D0 (en) 2017-02-10 2017-02-10 Method
PCT/GB2018/050374 WO2018146490A1 (en) 2017-02-10 2018-02-09 Rescue treatment of post operative nausea and vomiting

Publications (1)

Publication Number Publication Date
ZA201905212B true ZA201905212B (en) 2023-12-20

Family

ID=58462198

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/05212A ZA201905212B (en) 2017-02-10 2019-08-07 Rescue treatment of post operative nausea and vomiting

Country Status (13)

Country Link
US (4) US11357753B2 (enExample)
EP (1) EP3579831A1 (enExample)
JP (2) JP7333269B2 (enExample)
KR (2) KR20190111993A (enExample)
CN (2) CN122351229A (enExample)
AU (2) AU2018218310B2 (enExample)
BR (1) BR112019016565A2 (enExample)
EA (1) EA201991667A1 (enExample)
GB (1) GB201702250D0 (enExample)
IL (2) IL268591B2 (enExample)
MX (1) MX388736B (enExample)
WO (1) WO2018146490A1 (enExample)
ZA (1) ZA201905212B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
IT201900013524A1 (it) * 2019-07-31 2021-01-31 Laboratori Baldacci Spa Nuove formulazioni di amisulpride
BR112023000167A2 (pt) * 2020-07-06 2023-01-31 Acacia Pharma Ltd Terapia de náusea e vômito pós-operatórios

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1004020A (en) 1964-04-24 1965-09-08 Standard Telephones Cables Ltd Improvements in or relating to the mounting of electrical components
FR2415099A1 (fr) 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
GB9305593D0 (en) 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US6169094B1 (en) 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
DE102005013726A1 (de) 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
JP5433236B2 (ja) 2006-01-27 2014-03-05 アプタリス ファーマテック，インコーポレイテッド 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
WO2007096489A1 (fr) 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
PE20121483A1 (es) 2009-11-18 2012-12-02 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
AU2011268073B2 (en) 2010-06-18 2015-07-16 Takeda Pharmaceutical Company Limited D2 antagonists, methods of synthesis and methods of use
JP2016532660A (ja) 2013-10-08 2016-10-20 イノファーマ インク アプレピタント経口液体製剤
GB201506116D0 (en) * 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
GB201618425D0 (en) 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method

Also Published As

Publication number Publication date
US11357753B2 (en) 2022-06-14
BR112019016565A2 (pt) 2020-03-31
US12005042B2 (en) 2024-06-11
GB201702250D0 (en) 2017-03-29
IL268591B2 (en) 2023-04-01
JP2020506209A (ja) 2020-02-27
AU2018218310B2 (en) 2024-02-15
IL298486A (en) 2023-01-01
AU2024203155A1 (en) 2024-05-30
IL268591B (en) 2022-12-01
CN122351229A (zh) 2026-07-10
US20250367211A1 (en) 2025-12-04
JP7526244B2 (ja) 2024-07-31
KR20190111993A (ko) 2019-10-02
IL298486B2 (en) 2024-09-01
AU2018218310A1 (en) 2019-08-22
IL268591A (en) 2019-09-26
MX388736B (es) 2025-03-20
AU2024203155B2 (en) 2025-03-13
US20230100786A1 (en) 2023-03-30
CN110603036A (zh) 2019-12-20
US20200038369A1 (en) 2020-02-06
WO2018146490A1 (en) 2018-08-16
NZ756051A (en) 2024-04-26
JP7333269B2 (ja) 2023-08-24
EA201991667A1 (ru) 2020-02-11
US20240285579A1 (en) 2024-08-29
JP2023027213A (ja) 2023-03-01
EP3579831A1 (en) 2019-12-18
IL298486B1 (en) 2024-05-01
KR20240001288A (ko) 2024-01-03
NZ796242A (en) 2026-01-30
CA3052535A1 (en) 2018-08-16
US12329740B2 (en) 2025-06-17

Similar Documents

Publication Publication Date Title
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
MX2021002321A (es) Nuevos metodos.
IL268960A (en) 7,6,5,4-Tetrahydroisoxazazole (4,5-c) Pyridin-3-ol (thip) for use in the treatment of broken x syndrome
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
EP4512394A3 (en) Dosage forms and use thereof
NZ714963A (en) Compositions and methods for treating anemia
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
NZ605469A (en) Nalbuphine-based formulations and uses thereof
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
NZ726610A (en) A novel formulation of meloxicam
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
MX2016014699A (es) (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
MX388736B (es) Tratamiento de rescate de nausea y vomito post operatorio.
NZ751972A (en) Treatment of prurigo nodularis
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
AR102308A1 (es) Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico
PH12020500606A1 (en) Use of functionalized calcium carbonate as active ingredient
UA117833U (uk) Спосіб лікування синдрому післяопераційної нудоти та блювання у пацієнтів після лапароскопічної холецистектомії
NZ760052A (en) Methods of treatment for cystic fibrosis
MDS20160124U2 (ro) Metodă de profilaxie a limforeii prolongate în tratamentul radical al cancerului glandei mamare la pacientele cu diabet zaharat tip 2
MX2021004997A (es) Tratamiento y prevencion de la eyaculacion precoz (ep).